

CITATION REPORT

List of articles citing

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

DOI: 10.1007/s40262-016-0473-5
Clinical Pharmacokinetics, 2017, 56, 649-660.

Source: <https://exaly.com/paper-pdf/67774577/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 551-559	6.2	106
50	A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus. <i>Drugs and Aging</i> , 2017 , 34, 29-38	4.7	21
49	Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. <i>Clinical Drug Investigation</i> , 2017 , 37, 503-509	3.2	21
48	Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, S25-S37	8.1	208
47	Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?. <i>Clinical Drug Investigation</i> , 2017 , 37, 881-884	3.2	1
46	The First Hybrid Closed-Loop Insulin Pump: Will It Meet Its Potential?. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 140-141	8.1	3
45	Pharmacological Properties of Faster-Acting Insulin Aspart. <i>Current Diabetes Reports</i> , 2017 , 17, 101	5.6	17
44	Pharmakologische Eigenschaften des schneller wirksamen Insulins aspart (Faster-acting Insulin aspart). <i>Diabetologie Und Stoffwechsel</i> , 2017 , 12, 386-396	0.7	
43	Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1615-1622	6.7	22
42	Glucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story. <i>International Journal of Pharmaceutics</i> , 2018 , 544, 309-318	6.5	23
41	Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. <i>Journal of Diabetes Investigation</i> , 2018 , 9, 303-310	3.9	13
40	The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 245-256	6.7	52
39	Pharmacological variability of insulins degludec and glargine 300U/mL: Equivalent or not?. <i>Diabetes and Metabolism</i> , 2018 , 44, 1-3	5.4	4
38	Préparations insuliniques au cours de la dernière décennie.. <i>Medecine Des Maladies Metaboliques</i> , 2018 , 12, 113-127	0.1	5
37	[New technologies in diabetes treatment]. <i>Der Internist</i> , 2019 , 60, 912-916	0	
36	Insulin Pumps and Artificial Pancreas. 2019 , 245-258		0
35	How often patients on insulin therapy measure postprandial glycemia and modify insulin doses accordingly? From an on-line survey in insulin-treated diabetes patients in Spain. <i>Diabetes Research and Clinical Practice</i> , 2019 , 154, 43-51	7.4	1

34	Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2068-2075	6.7	15
33	Insulin. 2019 , 403-427		4
32	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 515-523	2.1	21
31	Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c. 2019 , 405-421		
30	Carbohydrate Intake in the Context of Exercise in People with Type 1 Diabetes. <i>Nutrients</i> , 2019 , 11,	6.7	6
29	Update on postprandial hyperglycaemia: the pathophysiology, prevalence, consequences and implications of treating diabetes. <i>Revista Clínica Espanola</i> , 2020 , 220, 57-68	0.7	1
28	Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes. <i>Revista Clínica Espanola</i> , 2020 , 220, 57-68	0.5	1
27	Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus. <i>Clinical Pharmacology in Drug Development</i> , 2020 , 9, 74-86	2.3	13
26	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 155-172	6.2	17
25	Home-based high-intensity interval training reduces barriers to exercise in people with type 1 diabetes. <i>Experimental Physiology</i> , 2020 , 105, 571-578	2.4	6
24	Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. <i>Diabetes Therapy</i> , 2020 , 11, 387-409	3.6	20
23	Biosimilars and Novel Insulins. <i>American Journal of Therapeutics</i> , 2020 , 27, e52-e61	1	3
22	Biosynthetic Human Insulin and Insulin Analogs. <i>American Journal of Therapeutics</i> , 2020 , 27, e42-e51	1	10
21	Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. <i>Clinical Therapeutics</i> , 2020 , 42, 1762-1777.	2.5	5
20	Urinary detection of rapid-acting insulin analogs in healthy humans. <i>Drug Testing and Analysis</i> , 2020 , 12, 1629-1635	3.5	7
19	The Evolution of Insulin and How it Informs Therapy and Treatment Choices. <i>Endocrine Reviews</i> , 2020 , 41,	27.2	48
18	Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 448-455	14.6	4
17	Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1389-1396	6.7	25

16	CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial. <i>BMJ Open</i> , 2021 , 11, e045650	3	
15	Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males. <i>Scientific Reports</i> , 2021 , 11, 9495	4.9	1
14	Si l'usage des insulines semi-synthétiques et biosynthétiques nous fait connaître. <i>Medecine Des Maladies Metaboliques</i> , 2021 , 15, 3S32-3S52	0.1	0
13	Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. <i>Artificial Organs</i> , 2021 , 45, 968-986	2.6	6
12	Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2670-2678	6.7	0
11	Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise. <i>Diabetes Technology and Therapeutics</i> , 2021 ,	8.1	2
10	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1789-1798	6.7	29
9	Thérapeutique des troubles glycémiques. 2019 , 141-252		
8	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. <i>Diabetes Mellitus</i> , 2020 , 23, 140-160	1.6	
7	Insulin discovery: A pivotal point in medical history. <i>Metabolism: Clinical and Experimental</i> , 2021 , 127, 154941	12.7	1
6	Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
5	Reduction in Postprandial Peak Glucose With Increased Technosphere Insulin Dosage. <i>Journal of Diabetes Science and Technology</i> , 193229682211106	4.1	0
4	In Silico Evaluation of the Medtronic 780G System While Using the GS3 and Its Calibration-Free Successor, the G4S Sensor.		0
3	The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. 2022 , 24, 726-736		0
2	A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. 2022 , 24, 681-696		2
1	Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice. 2022 , 25, 458-467		0